PDGFRA and acute myeloid leukemia: This suggests that the underlying mechanism of IDH2 mutant-specific sensitivity to dasatinib may differ from our observed IDH1 mutant-specific dasatinib sensitivity and may be related to other dasatinib targets than PDGFRA. This would be compatible with the data from Wilson et al. reporting differences in global hypermethylation patterns of IDH1-mut and IDH2-mut AML [36].